A part of Watch Media

MedWatchSunday5 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
13/12/2022at 09:42

Novo Nordisk to test app and heart disease antibody in phase III trial

An unnamed app features in new late-stage clinical plans for the Danish drugmaker, which is looking into a drug candidate it got from the acquisition of Corvidia Therapeutics.
Photo: Tidsvilde Stine/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

Next year, Novo Nordisk may very well be able to initiate a phase III trial of antibody ziltivekimab, which stems from the multimillion-dollar acquisition of US-based Corvidia Therapeutics, alongside an app.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

    Novo Nordisk targets combined launch of insulin app and once-weekly insulin

    For subscribers

  • Jeppe Theisen, vice president and general manager for Denmark and Iceland at Novo Nordisk | Photo: Novo Nordisk / PR

    Novo Nordisk to launch sought-after obesity drug in Denmark

    For subscribers

  • Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

    Novo Nordisk's combination drug for obesity and diabetes shows positive results, heads to phase III

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Photo: Magnus Møller
Pharma & biotech

Extensive layoffs at Leo Pharma – 300 jobs lost

On Thursday, Leo Pharma executed a firing round among employees primarily at the company’s R&D division. 

For subscribers

Photo: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Novo Nordisk’s days of being alone to market an approved weight-loss drug are numbered as firms position themselves to split the market that’ll reach USD 30bn by 2030.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Senior Clinical Project Manager

  • Supply Chain Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Lead Data Architect

  • Experienced Patent Counsel

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Regulatory Affairs Professional

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Sr. Director, Drug Safety Physician

  • Clinical Operational Associate

  • Application Manager

See all jobs

Jobs

  • Senior Clinical Project Manager

  • Supply Chain Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Lead Data Architect

  • Experienced Patent Counsel

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Regulatory Affairs Professional

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Sr. Director, Drug Safety Physician

  • Clinical Operational Associate

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge